StockNews.com assumed coverage on shares of iBio (NYSE:IBIO – Free Report) in a report released on Saturday. The firm issued a sell rating on the stock.
iBio Trading Up 7.3 %
Shares of NYSE:IBIO opened at $1.91 on Friday. The company has a debt-to-equity ratio of 0.04, a quick ratio of 0.91 and a current ratio of 0.91. iBio has a one year low of $1.02 and a one year high of $26.20.
iBio (NYSE:IBIO – Get Free Report) last issued its quarterly earnings data on Friday, February 9th. The company reported ($2.42) earnings per share (EPS) for the quarter.
iBio Company Profile
iBio, Inc, a biotechnology company, engages in the development of precision antibodies in the United States. It offers IBIO-100, a preclinical anti-fibrotic program for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis; and EngageTx platform, which provides an optimized CD3 T-cell engager antibody panel.
Further Reading
- Five stocks we like better than iBio
- Russell 2000 Index, How Investors Use it For Profitable Trading
- Charles Schwab Fortifies its Uptrend on EPS Beat
- How to Calculate Return on Investment (ROI)
- Lockheed Martin Stock Aims for a Fresh All-Time High
- What Does a Gap Up Mean in Stocks? How to Play the Gap
- Beyond the Halving: The Future of Bitcoin Mining Stocks
Receive News & Ratings for iBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iBio and related companies with MarketBeat.com's FREE daily email newsletter.
